This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., To Develop Disease Treatments Based On Cannabinoids

SILVER SPRING, Md., Feb. 12, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of human diseases, announced today its subsidiary, Medical Marijuana Sciences, Inc., will develop treatments for human diseases by employing cannabinoids from marijuana (Cannabis sativa).

The use of Cannabis for medicinal purposes dates back more than 3,000 years. It was introduced into Western medicine in the 1840s. Its analgesic, sedative, anti-inflammatory, anticonvulsant, and antispasmodic effects formed the original basis for its use. The components of marijuana that have shown medical activity are known as "cannabinoids", approximately 70 cannabinoids of which have been found in Cannabis sativa.

Cannabinoids can be classified into three groups: (1) naturally-occurring cannabinoids – examples are Delta 9- tetrahydrocannabinol (THC) and cannabidiol (CBD); (2) endocannabinoids – these are synthesized "on demand" within the body by particular types of cells - examples include anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG); (3) synthetic cannabinoids – an example is nabilone, which has been approved by the U.S. Food and Drug Administration for the treatment of cancer-related side effects.

Since the 1970s, cannabinoids have been known to alleviate pain, nausea, and vomiting. These compounds have been particularly effective against cancer-related pain and in enhancing the appetites of cancer patients which are typically diminished. The latter discovery has led to finding that cannabinoids can help relieve cancer-related cachexia, a "wasting" syndrome composed of weight loss, muscle atrophy, fatigue, weakness, and loss of appetite.

"Cannabinoids have been investigated both in vivo and in vitro for many years targeting a wide array of diseases and disorders, thus amassing a large portfolio of promising research data," said Dr. Gerald Crabtree, Chief Operating Officer of Nuvilex.  "Naturally-occurring cannabinoids such as THC and CBD are excellent cornerstones upon which our subsidiary, Medical Marijuana Sciences, Inc. can build disease treatments. There have been many reports in scientific journals and other literature that contribute to our understanding of how these marijuana constituents work, as well as reports of their activity against various diseases in preclinical test systems. We intend to use our expertise to establish ourselves as a leading contributor to the growing database of information demonstrating the therapeutic benefits of cannabinoids in a clinical setting."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs